세계의 유전자 치료 플랫폼 시장 규모, 점유율, 동향 분석 보고서 : 플랫폼 유형별, 치료 용도별, 전달 모드별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Gene Therapy Platform Market Size & Trends:

The global gene therapy platform market size was estimated at USD 2.14 billion in 2024 and is projected to grow at a CAGR of 15.2% from 2025 to 2030. The growth is driven by several key drivers, including rapid technological advancements, increasing prevalence of genetic and chronic diseases, growing investments and funding in biopharmaceutical research, and supportive regulatory frameworks facilitating faster approvals.

Innovations in viral vector technologies, gene editing tools including CRISPR, integration of AI and automation in manufacturing are enhancing therapy precision and production efficiency. For instance, in March 2023, Catalent is enhancing its UpTempo AAV platform to speed up the development of gene therapies.

The increasing number of FDA approvals for gene therapies targeting rare and genetic diseases has validated the clinical potential of these platforms, encouraging investment and R&D. For instance, in December 2023[, CRISPR-based therapies, like Exagamglogene autotemcel (Casgevy), received FDA approval for sickle cell disease and beta-thalassemia, marking a significant milestone in gene therapy. These breakthroughs are pushing the field forward, enabling more efficient technology for various genetic disorders.

The rising prevalence of genetic disorders and chronic diseases worldwide, is fueling demand for gene therapies that target disease at the molecular level. Conditions such as cystic fibrosis, hemophilia, spinal muscular atrophy, and various cancers are increasingly treated with gene therapy approaches that offer potentially curative outcomes. The World Health Organization (WHO) in 2024 projected a sharp increase in cancer cases globally, with over 35 million new cases expected by 2050, up 77% from 2022. This growing patient pool creates urgent demand for advanced treatments, driving investment and innovation in gene therapy technologies to address unmet medical needs.

Moreover, regulatory support for innovative therapies is driving market growth. Regulatory agencies, including the FDA and the European Medicines Agency (EMA), have streamlined approval processes for gene therapies, recognizing their transformative potential. In addition, regulatory incentives such as fast-track designations and orphan drug status further support the development of gene therapies. These measures help reduce development timelines and encourage the introduction of new treatments to address unmet medical needs.

The COVID-19 pandemic significantly impacted the market, disrupting clinical trials, manufacturing, and supply chains. The increased demand for raw materials for COVID-19 vaccine production caused shortages, affecting the availability of essential components for gene therapy manufacturing. Despite these challenges, the pandemic also spurred innovation, with some gene therapy developers adapting their efforts toward COVID-19-related therapeutics and vaccines, highlighting the resilience and potential of the gene therapy sector.

Global Gene Therapy Platform Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global gene therapy platform market report based on platform type, application, delivery method, end use, and region.

• Platform Type Outlook (Revenue, USD Million, 2018 - 2030)
• Viral Vector Platforms
  • Adeno-associated Virus (AAV)
  • Lentivirus
  • Retrovirus
  • Adenovirus
  • Herpes Simplex Virus (HSV)
• Non-Viral Vector Platforms
  • Lipid Nanoparticles (LNPs)
  • Electroporation & Microinjection Platforms
  • Polymer-based Delivery Systems
  • Naked DNA/RNA Delivery
• Gene Editing Platforms
  • CRISPR-Cas Systems
  • TALENs
  • ZFNs
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Oncology
• Rare Genetic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Ophthalmic Diseases
• Hematological Disorders (e.g., Hemophilia, Sickle Cell)
• Musculoskeletal Disorders
• Infectious Diseases (e.g., HIV, COVID-19 adjunct therapies)
• Delivery Mode Outlook (Revenue, USD Million, 2018 - 2030)
• In Vivo Gene Therapy
• Ex Vivo Gene Therapy
  • Autologous Cell-Based Gene Therapy
  • Allogeneic Cell-Based Gene Therapy
• Others (In-situ Gene therapy)
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Contract Development & Manufacturing Organizations (CDMOs)
• Hospitals & Gene Therapy Centers
• Regional Outlook (Revenue, USD Million, 2018-2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Scope
  • 1.2.1. Platform Type
  • 1.2.2. Application
  • 1.2.3. Delivery Method
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Platform Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Delivery Method Outlook
  • 2.2.4. End Use Outlook
  • 2.2.5. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Therapy Platform Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising prevalence of genetic disorders
    • 3.2.1.2. Advancements in gene editing technologies
    • 3.2.1.3. Supportive regulatory frameworks
    • 3.2.1.4. Growing investment and strategic partnerships
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of development and treatment
  • 3.2.3. Industry Challenges and Opportunity Analysis
• 3.3. Gene Therapy Platform Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological Landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
• 3.4. Regulatory Framework
• 3.5. Emerging Technologies
• 3.6. Impact of COVID 19 on the Gene Therapy Platform Market
• 3.7. Case Study & Insights

Chapter 4. Gene Therapy Platform Market: Platform Type Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Platform Type Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Gene Therapy Platform Market: By Platform Type, 2018 to 2030
• 4.5. Viral Vector Platforms
  • 4.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Adeno-associated Virus (AAV)
    • 4.5.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Lentivirus
    • 4.5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Retrovirus
    • 4.5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Adenovirus
    • 4.5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.6. Herpes Simplex Virus (HSV)
    • 4.5.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Non-Viral Vector Platforms
  • 4.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Lipid Nanoparticles (LNPs)
    • 4.6.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Electroporation & Microinjection Platforms
    • 4.6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Polymer-based Delivery Systems
    • 4.6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Naked DNA/RNA Delivery
    • 4.6.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Gene Editing Platforms
  • 4.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.2. CRISPR-Cas Systems
    • 4.7.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.3. TALENs
    • 4.7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.4. ZFNs
    • 4.7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Gene Therapy Platform Market: Application Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Gene Therapy Platform Market: By Application, 2018 to 2030
• 5.5. Oncology
  • 5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Rare Genetic Disorders
  • 5.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Cardiovascular Diseases
  • 5.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Neurological Disorders
  • 5.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Ophthalmic Diseases
  • 5.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Hematological Disorders (e.g., Hemophilia, Sickle Cell)
  • 5.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Musculoskeletal Disorders
  • 5.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.12. Infectious Diseases (e.g., HIV, COVID-19 adjunct therapies)
  • 5.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Gene Therapy Platform Market: Delivery Method Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. Delivery Mode Market Share Analysis, 2024 & 2030
• 6.3. Segment Dashboard
• 6.4. Gene Therapy Platform Market: By Delivery Mode, 2018 to 2030
• 6.5. In Vivo Gene Therapy
  • 6.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Ex Vivo Gene Therapy
  • 6.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Autologous Cell-Based Gene Therapy
    • 6.6.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Allogeneic Cell-Based Gene Therapy
    • 6.6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others (In-situ Gene therapy)
  • 6.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Gene Therapy Platform Market: End Use Estimates & Trend Analysis

• 7.1. Definition and Scope
• 7.2. End Use Market Share Analysis, 2024 & 2030
• 7.3. Segment Dashboard
• 7.4. Gene Therapy Platform Market: By End Use, 2018 to 2030
• 7.5. Pharmaceutical & Biotechnology Companies
  • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Academic & Research Institutions
  • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Contract Development & Manufacturing Organizations (CDMOs)
  • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Hospitals & Gene Therapy Centers
  • 7.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Gene Therapy Platform Market: Regional Estimates & Trend Analysis by Platform Type, Therapeutic Application, Delivery Method, and End Use

• 8.1. Definition and Scope
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Regional Market Dashboard
• 8.4. Regional Market Snapshot
• 8.5. SWOT Analysis
  • 8.5.1. North America
  • 8.5.2. Europe
  • 8.5.3. Asia Pacific
  • 8.5.4. Latin America
  • 8.5.5. Middle East & Africa
• 8.6. Gene Therapy Platform Market Share, By Region, 2024 & 2030, USD Million
• 8.7. North America
  • 8.7.1. North America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. U.S.
    • 8.7.2.1. U.S. Key Country Dynamics
    • 8.7.2.2. Regulatory Landscape
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. U.S. Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Canada
    • 8.7.3.1. Canada Key Country Dynamics
    • 8.7.3.2. Regulatory Landscape
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Canada Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. Mexico
    • 8.7.4.1. Mexico Key Country Dynamics
    • 8.7.4.2. Regulatory Landscape
    • 8.7.4.3. Competitive Insights
    • 8.7.4.4. Mexico Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Europe
  • 8.8.1. Europe Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. UK
    • 8.8.2.1. UK Key Country Dynamics
    • 8.8.2.2. Regulatory Landscape
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. U.K. Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Germany
    • 8.8.3.1. Germany Key Country Dynamics
    • 8.8.3.2. Regulatory Landscape
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Germany Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. France
    • 8.8.4.1. France Key Country Dynamics
    • 8.8.4.2. Regulatory Landscape
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. France Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Italy
    • 8.8.5.1. Italy Key Country Dynamics
    • 8.8.5.2. Regulatory Landscape
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Italy Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.6. Spain
    • 8.8.6.1. Spain Key Country Dynamics
    • 8.8.6.2. Regulatory Landscape
    • 8.8.6.3. Competitive Insights
    • 8.8.6.4. Spain Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.7. Sweden
    • 8.8.7.1. Sweden Key Country Dynamics
    • 8.8.7.2. Regulatory Landscape
    • 8.8.7.3. Competitive Insights
    • 8.8.7.4. Sweden Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.8. Denmark
    • 8.8.8.1. Denmark Key Country Dynamics
    • 8.8.8.2. Regulatory Landscape
    • 8.8.8.3. Competitive Insights
    • 8.8.8.4. Denmark Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.9. Norway
    • 8.8.9.1. Norway Key Country Dynamics
    • 8.8.9.2. Regulatory Landscape
    • 8.8.9.3. Competitive Insights
    • 8.8.9.4. Norway Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.9. Asia Pacific
  • 8.9.1. Asia Pacific Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.2. China
    • 8.9.2.1. China Key Country Dynamics
    • 8.9.2.2. Regulatory Landscape
    • 8.9.2.3. Competitive Insights
    • 8.9.2.4. China Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.3. Japan
    • 8.9.3.1. Japan Key Country Dynamics
    • 8.9.3.2. Regulatory Landscape
    • 8.9.3.3. Competitive Insights
    • 8.9.3.4. Japan Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.4. India
    • 8.9.4.1. India Key Country Dynamics
    • 8.9.4.2. Regulatory Landscape
    • 8.9.4.3. Competitive Insights
    • 8.9.4.4. India Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.5. South Korea
    • 8.9.5.1. South Korea Key Country Dynamics
    • 8.9.5.2. Regulatory Landscape
    • 8.9.5.3. Competitive Insights
    • 8.9.5.4. South Korea Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.6. Australia
    • 8.9.6.1. Australia Key Country Dynamics
    • 8.9.6.2. Regulatory Landscape
    • 8.9.6.3. Competitive Insights
    • 8.9.6.4. Australia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.7. Thailand
    • 8.9.7.1. Thailand Key Country Dynamics
    • 8.9.7.2. Regulatory Landscape
    • 8.9.7.3. Competitive Insights
    • 8.9.7.4. Thailand Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.10. Latin America
  • 8.10.1. Latin America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.10.2. Brazil
    • 8.10.2.1. Brazil Key Country Dynamics
    • 8.10.2.2. Regulatory Landscape
    • 8.10.2.3. Competitive Insights
    • 8.10.2.4. Brazil Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.10.3. Argentina
    • 8.10.3.1. Argentina Key Country Dynamics
    • 8.10.3.2. Regulatory Landscape
    • 8.10.3.3. Competitive Insights
    • 8.10.3.4. Argentina Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.11. Middle East and Africa
  • 8.11.1. Middle East and Africa Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.2. South Africa
    • 8.11.2.1. South Africa Key Country Dynamics
    • 8.11.2.2. Regulatory Landscape
    • 8.11.2.3. Competitive Insights
    • 8.11.2.4. South Africa Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.3. Saudi Arabia
    • 8.11.3.1. Saudi Arabia Key Country Dynamics
    • 8.11.3.2. Regulatory Landscape
    • 8.11.3.3. Competitive Insights
    • 8.11.3.4. Saudi Arabia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.4. UAE
    • 8.11.4.1. UAE Key Country Dynamics
    • 8.11.4.2. Regulatory Landscape
    • 8.11.4.3. Competitive Insights
    • 8.11.4.4. UAE Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.5. Kuwait
    • 8.11.5.1. Kuwait Key Country Dynamics
    • 8.11.5.2. Regulatory Landscape
    • 8.11.5.3. Competitive Insights
    • 8.11.5.4. Kuwait Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share Analysis
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Lonza
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments
  • 9.4.2. BioIT
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments
  • 9.4.3. Autolomous Ltd
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments
  • 9.4.4. Hypertrust Patient Data Care (Part of Accenture)
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments
  • 9.4.5. IBM
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments
  • 9.4.6. L7 Informatics, Inc.
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments
  • 9.4.7. TrakCel
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments
  • 9.4.8. IDBS
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments
  • 9.4.9. Novartis
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments
  • 9.4.10. SAP SE
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments
  • 9.4.11. DEEP GENOMICS
    • 9.4.11.1. Participant's Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Recent Developments
  • 9.4.12. ElevateBio
    • 9.4.12.1. Participant's Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Recent Developments
  • 9.4.13. Sarepta Therapeutics, Inc.
    • 9.4.13.1. Participant's Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Recent Developments
  • 9.4.14. CRISPR Therapeutics
    • 9.4.14.1. Participant's Overview
    • 9.4.14.2. Financial Performance
    • 9.4.14.3. Product Benchmarking
    • 9.4.14.4. Recent Developments
  • 9.4.15. Precision BioSciences
    • 9.4.15.1. Participant's Overview
    • 9.4.15.2. Financial Performance
    • 9.4.15.3. Product Benchmarking
    • 9.4.15.4. Recent Developments
  • 9.4.16. AstraZeneca
    • 9.4.16.1. Participant's Overview
    • 9.4.16.2. Financial Performance
    • 9.4.16.3. Product Benchmarking
    • 9.4.16.4. Recent Developments
  • 9.4.17. Andelyn Biosciences
    • 9.4.17.1. Participant's Overview
    • 9.4.17.2. Financial Performance
    • 9.4.17.3. Product Benchmarking
    • 9.4.17.4. Recent Developments
  • 9.4.18. Renova Therapeutics
    • 9.4.18.1. Participant's Overview
    • 9.4.18.2. Financial Performance
    • 9.4.18.3. Product Benchmarking
    • 9.4.18.4. Recent Developments